CABA * Stock Overview
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cabaletta Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$71.76 |
| 52 Week High | US$418.23 |
| 52 Week Low | US$71.76 |
| Beta | 2.4 |
| 11 Month Change | 0% |
| 3 Month Change | -52.79% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| CABA * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how CABA * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how CABA * performed against the MX Market.
Price Volatility
| CABA * volatility | |
|---|---|
| CABA * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: CABA *'s share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CABA *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 137 | Steven Nichtberger | www.cabalettabio.com |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.
Cabaletta Bio, Inc. Fundamentals Summary
| CABA * fundamental statistics | |
|---|---|
| Market cap | Mex$3.80b |
| Earnings (TTM) | -Mex$1.74b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs CABA * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CABA * income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$89.98m |
| Earnings | -US$89.98m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CABA * perform over the long term?
See historical performance and comparison